Phase 2 N=16 Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With an Improvement of ≥ 4 Points on the ADAS-cog/11 — 0 responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=183 Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
Respiratory Tract Infection · Respiratory Syncytial Virus
Primary: Percentage of Participants Who Experienced At Least One Solicited Injection Site Adverse Event (AE) — 3; 3; 3; 2 Participants
Phase 2 N=38 A Study of LY3451838 in Participants With Migraine
Migraine
Primary: Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month — -3.8; -2.7 migraine days per month
Phase 2 N=13 Opioid Modulation and Neural Reward Activation in Healthy Adults
Alcohol Drinking · Opioid Use, Unspecified
Primary: Change in Brain Activation to Reward Between Placebo and Active Medication — 0.25; 0.26 percentage signal change
Phase 2 N=12 Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
Phase 2 N=33 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
Niemann-Pick Disease, Type C
Primary: Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021] — 0.86 score on a scale — p=0.029
Phase 2 N=118 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Metastatic Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7 · Stage IIIC Breast Cancer AJCC v7
Primary: Number of Participants With Progression Free Survival (PFS) at 12 Months — 8; 16 Participants
Phase 2 N=19 Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Gastrointestinal Cancer · Biliary Tract Cancer
Primary: Part 1: Establish the Maximum Tolerated Dose (MTD) — 100 mg
Phase 2 N=19 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 0 Percentage of participants
Phase 2 N=86 A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Day 14 — 6.04; 6.14; 5.92; 6.03 units on…
Phase 2 N=123 Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Phase 2 N=40 A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
Helicobacter Pylori Infection
Primary: The Eradication Rate of Helicobacter Pylori Infection — 0; 3; 4; 8 Participants
Phase 2 N=87 Effects of Vivatlac Baby on Crying Behavior of Colicky Babies
Infantile Colic
Primary: Number of Participants With a Reduction of Days Crying Equal or More Than 50 Percent From Baseline — 6; 39 Participants — p=<0.0001
Phase 2 N=155 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale
Phase 2 N=7 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants